The Liquid Biopsy Market was valued at USD 13.31 billion in 2025 and is projected to reach USD 36.51 billion by 2034, expanding at a CAGR of 11.9% from 2026 to 2034, according to Polaris Market Research. The 2026 value is USD 14.86 billion. For diagnostics developers, laboratories and investors, the underlying science matters as much as the headline figures. This article reviews the biomarkers, sample types and detection technologies that define the competitive landscape.

Why Liquid Biopsy Is Gaining Attention

Liquid biopsy uses blood or other body fluids to analyze disease-related signals, in contrast to a tissue procedure that requires solid tissue. Polaris cites several drivers: rising global cancer incidence, demand for early detection and monitoring, the growth of personalized medicine and the preference for minimally invasive testing. The report references World Health Organization figures from February 2024, which show nearly 20 million new cancer cases in 2022, projected to reach 35 million annually by 2050. The report also states that liquid-based testing can be repeated easily and delivers faster results than tissue-based testing, although it may miss some tumor details.

Circulating Tumor DNA Leads the Biomarker Segment

Among biomarkers, the report covers circulating tumor cells, circulating tumor DNA, extracellular vesicles and others. The circulating tumor DNA segment held the largest share in 2025, at 20.0%. Its position reflects how widely the biomarker is used in clinical and research settings: detecting circulating tumor DNA in blood can help identify early-stage cancer, and tracking changes in tumor DNA during therapy supports treatment monitoring.

Extracellular Vesicles: The Fastest-Growing Biomarker

While circulating tumor DNA is the largest biomarker segment, extracellular vesicles are projected to grow fastest over the forecast period, according to the report. The page does not provide a separate growth rate for this segment, so the finding should be read as a directional signal. For developers, it suggests that research and product pipelines focused on extracellular vesicles may attract increasing attention alongside established markers.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

https://www.polarismarketresearch.com/industry-analysis/liquid-biopsy-market 

Sequencing and PCR Technologies

On the technology side, the market is divided into multi-gene parallel analysis and single gene analysis. The multi-gene parallel analysis segment, which the report associates with next-generation sequencing, held the largest share in 2025 at 54.0%. Single gene analysis, based on PCR microarrays, is expected to grow fastest.

Polaris lists technological advances in next-generation sequencing and digital PCR among the factors improving sensitivity and accuracy. Because limited sensitivity in early-stage cancer detection is also identified as a challenge, continued progress in digital PCR and sequencing platforms is directly relevant to clinical adoption. The combination of multi-gene parallel analysis and single gene approaches gives laboratories flexibility to match the test to the clinical question.

Sample Types: Blood Dominates

By sample type, the blood sample segment held an 86.0% share in 2025. Other sample types, including urine, saliva and cerebrospinal fluid, are expected to see the highest growth, at a CAGR of 12.8%. This indicates that while blood remains the standard, assay developers are exploring additional fluids. The report's segmentation also covers cancer, reproductive health and other applications, and end users ranging from hospitals and laboratories to specialty clinics and academic and research centers.

The Role of AI

The report highlights several ways AI is influencing the field: broadening applications from oncology to neurological and cardiovascular diseases, enabling ultra-sensitive detection of biomarkers such as ctDNA and extracellular vesicles, and automating data analysis and reporting to reduce manual errors and turnaround times.

Recent Product and Partnership Activity

Several developments illustrate the pace of innovation:

• February 2026: BillionToOne expanded its Northstar platform, adding two new liquid biopsy applications to Northstar Select.
• July 2025: NeoGenomics launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling test for advanced solid tumors.
• April 2025: Guardant Health announced a collaboration with Pfizer using its Infinity Smart Liquid Biopsy platform to support development and commercialization of cancer therapies.

Regional Perspective

North America held a 39.0% share in 2025, with the U.S. dominating the region. Asia Pacific is the fastest-growing region, at a CAGR of 14.2%, with China highlighted as a major driver. The report notes regulatory hurdles and the need for standardized testing procedures, especially in Asia Pacific, along with high test costs and limited access in smaller healthcare facilities and developing regions. Germany is highlighted as a major European market.

Polaris rates the threat of new entrants as low and rivalry among existing firms as high, with supplier power, buyer power and the threat of substitutes rated moderate.

Key Players

Leading companies in the Liquid Biopsy Market include F. Hoffmann-La Roche Ltd; Illumina, Inc.; Guardant Health, Inc.; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific, Inc.; Natera, Inc.; Exact Sciences Corporation; Adaptive Biotechnologies Corporation; Myriad Genetics, Inc.; and NeoGenomics Laboratories, Inc.

Conclusion

The Liquid Biopsy Market is being shaped by identifiable scientific building blocks: circulating tumor DNA as the largest biomarker segment, extracellular vesicles as the fastest-growing, multi-gene parallel analysis as the leading technology, and continued advances in next-generation sequencing and digital PCR. Cost, sensitivity and regulatory standardization remain challenges, but strong demand for minimally invasive testing supports the outlook. Companies that combine analytical performance with clinical evidence are best positioned to compete.

More Trending Latest Reports By Polaris Market Research:

Residual DNA Testing Market

Artificial Intelligence (AI) in Medical Imaging Market

Carbon Capture, Utilization and Storage Market

Warehouse Automation Market

Multi Agent Systems Market

Digital Pharmacy Market

Osteopontin Market

Smart Transportation Market

Quantum AI Market